Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Takeda Prepping for Japan Trial of Moderna COVID-19 Vaccine: MHLW Official
November 18, 2020
- Drug Makers Disclosing as Much Cost Info as Possible in Price Negotiations, JPMA Chief Rebuts Concerns Aired in Project Review
November 17, 2020
- Experts Urge Transparency for DPO/CEA Organization, Stringent Pricing for Cost-Based Products: Govt Project Review
November 17, 2020
- With Consensus on 13 Topics Delayed by COVID-19, ICH Expected to Restrict Selection of New Topics at Virtual Assembly
November 16, 2020
- “No Comment with Prejudgment” on COVID-19 Shots for Children: Minister
November 16, 2020
- PMDA Reviewing New Safety Risks for Soliris, Venclexta/Noxafil
November 16, 2020
- MHLW to Continue Follow-Up on Veklury’s Safety/Efficacy Info: Official
November 16, 2020
- MHLW Weighs COVID-19 Vaccinations outside Medical Institutions
November 16, 2020
- COVID-19 Vaccinations for HCPs Not Mandatory: Health Minister
November 16, 2020
- HPV Vaccine Is “Social Justice”: LDP Lawmaker
November 13, 2020
- No Consensus on Flu Vaccines’ Efficacy against COVID-19: NIID Chief
November 12, 2020
- Japan to Give Ultracold Chain-Required COVID-19 Shots to Certain People in Short Period: Minister
November 12, 2020
- Lower House Health Committee Starts Debate on Immunization Bill; Minister Says to Publish PAFSC Meeting Minutes ASAP
November 12, 2020
- Chuikyo’s Drug Pricing Subcommittee to Meet after 4-Month Hiatus to Discuss Off-Year Re-Pricing, Hear Industry Views
November 12, 2020
- Chuikyo Payer Rep Calls for Cost-Effectiveness Assessment of Drugs Used Together with Medical Devices
November 12, 2020
- Japan’s 1st Therapeutic App OK’ed for Health Coverage, Due for Release on Dec. 1
November 12, 2020
- LDP Lawmakers Leery of Off-Year Drug Re-Pricing to Meet on Nov. 26
November 11, 2020
- PM Suga Vows Transparency in COVID-19 Vaccine Review as Immunization Bill Enters Diet Deliberations
November 11, 2020
- Oral Semaglutide, Gilead JAK Inhibitor, Takeda’s PARP Med OK’ed for Listing on Nov. 18
November 11, 2020
- MHLW Says to Publish PAFSC Minutes for COVID-19 Vaccines in 3 Weeks, but Opposition Parties Unimpressed
November 10, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…